Introduction Nontuberculous mycobacterial (NTM) lung disease (LD) is the most common
clinical manifestation of NTM infection and is a growing health concern. Up to 85% of NTM …

Non-tuberculous mycobacterial pulmonary disease (NTM-PD) poses a substantial patient,
healthcare, and economic burden. Managing NTM-PD remains challenging, and factors …

Microbial infections caused by a variety of drug-resistant microorganisms are more common,
but there are fewer and fewer approved new antimicrobial chemotherapeutics for systemic …

Periodontitis is caused by oral flora imbalance, which leads to immune imbalance.
Porphyromonas gingivalis is a keystone pathogen in periodontitis, causing the blooming of …

Background Pulmonary fibrosis is a chronic progressive fibrotic interstitial lung disease
characterized by excessive extracellular matrix (ECM) deposition caused by activated …

Non-tuberculosis mycobacteria (NTM) can cause severe respiratory infection in patients with
underlying pulmonary conditions, and these infections are extremely difficult to treat. In this …

Tuberculosis (TB) is an infectious disease that annually affects millions of people, and
resistance to available antibiotics has exacerbated this situation. Another notable …

The use of nanomaterials in gene editing and synthetic biology has emerged as a pivotal
strategy in the pursuit of refined treatment methodologies for pulmonary disorders. This …

Abstract Background Mycobacterium abscessus (Mabs), a rapidly growing Mycobacterium
species, is considered an MDR organism. Among the standard antimicrobial multi-drug …

Purpose Real-world data on antibiotic management of nontuberculous mycobacterial lung
disease (NTM-LD) is limited for many countries. This study aimed to evaluate real-world …